Download PDF
Thromb Haemost 1994; 72(06): 887-892
DOI: 10.1055/s-0038-1648979
Original Article
Schattauer GmbH Stuttgart

Fibrinolytic Activity in Blood Is Distributed over a Cellular and the Plasma Fraction which Can Be Modulated Separately

J J J van Giezen
1   Solvay Duphar B. V., Dept. of Biotechnology, Weesp, The Netherlands
,
J E Chung-A-Hing
1   Solvay Duphar B. V., Dept. of Biotechnology, Weesp, The Netherlands
,
C B Vegter
1   Solvay Duphar B. V., Dept. of Biotechnology, Weesp, The Netherlands
,
B N Bouma
2   University Hospital Utrecht, Dept. of Haematology, Utrecht, The Netherlands
,
J W C M Jansen
1   Solvay Duphar B. V., Dept. of Biotechnology, Weesp, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 01 July 1993

Accepted after resubmission 18 August 1994

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Blood fibrinolytic activity is mediated by plasma and cellular components. We have studied blood fibrinolytic activity in different species and investigated the distribution pattern in rats after modulation with PAF, dexamethasone, or retinoic acid. Whole blood and plasma activity were measured in an assay system using human or endogenous fibrin as substrate. When human fibrin was used as substrate marked species differences in distribution of fibrinolytic activity were observed. In rat and murine blood most fibrinolytic activity was associated with the plasma fraction (70% and 50% respectively) while in human and canine blood the plasma fraction contained only 30% of the blood fibrinolytic activity. When endogenous fibrin was used as substrate the distribution pattern of fibrinolytic activity in rat blood changed dramatically. Less than 25% of the blood fibrinolytic activity was now present in the plasma fraction.

The fibrinolytic system was further investigated in rats using specific inhibitors of proteolytic activity. Blood fibrinolytic activity could be inhibited for 33% by antibodies raised against t-PA and 60% inhibition was obtained in the presence of amiloride. No significant effect of elas-tinal (an inhibitor of elastase) could be detected. Plasma fibrinolytic activity was not affected by these inhibitors. The fibrinolytic activity in plasma could be enhanced about 100-fold after i. v. PAF administration (10 μg/kg). This extra fibrinolytic activity could be fully blocked by antibodies raised against t-PA. Oral administration of dexamethasone or retinoic acid affected blood fibrinolytic activity by modulating selectively the activity mediated by the cellular fraction. Dexamethasone treatment (1 mg/kg) resulted in a 59% decrease of this fibrinolytic activity. Retinoic acid treatment (3 mg/kg) resulted in a 69% increase of the fibrinolytic activity in this phase. Both compounds affected selectively the t-PA activity.

We conclude that 1) the plasma as well as the cellular fraction contribute to the blood fibrinolytic activity; 2) the plasma derived fibrinolytic activity as such is a minor part of the total whole blood fibrinolytic activity (the mouse is an exception); 3) the rat blood fibrinolytic activity is evoked by u-PA (two third) and t-PA (one third) mediated processes; 4) the blood fibrinolytic activity can be modulated, in contrast to the plasma activity as such, by retinoic acid or dexamethasone; 5) the plasma fibrinolytic activity is subject to modulation by compounds which evoke a direct PA increase.

 

  • References

  • 1 Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296: 525-529
    CrossrefPubMedGoogle Scholar
  • 2 Langleben D, Moroz LA. Participation of blood cells in exercise-induced fibrinolysis. Thromb Res 1985; 39: 733-740
    CrossrefPubMedGoogle Scholar
  • 3 Moroz LA. Non-nlasmin-mediated fibrinolysis. Sem Thromb Haemost 1984; 10: 80-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Castellote JC, Grau E, Linde MA, Pujol-Moix N, Rutllant LI. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb Haemost 1990; 63: 67-71
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Unkeless JC, Gordon S, Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med 1974; 139: 834-850
    CrossrefPubMedGoogle Scholar
  • 6 Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-1668
    CrossrefPubMedGoogle Scholar
  • 7 Chapman HA, Yang X, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. J Immunol 1990; 145: 3398-3405
    CrossrefPubMedGoogle Scholar
  • 8 Schwartz BS, Bradshaw JD. Regulation plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. Blood 1989; 74: 1644-1650
    PubMedGoogle Scholar
  • 9 Langleben D, Moroz LA. Interspecies variation in the cellular phase of blood fibrinolytic activity. PSEBM 1991; 196: 270-272
    PubMedGoogle Scholar
  • 10 Van Giezen JJJ, Jansen JWCM. Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thromb Haemost 1992; 68: 69-73
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Kooistra T, Opdenberg JP, Toet K, Hendriks HFJ, Van den Hoogen RM, Emeis JJ. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost 1991; 65: 565-572
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Baillie AJ, Sim AK. Activation of the fibrinolytic enzyme system in laboratory animals and in man. Thromb Diath Haemorrh 1971; 25: 499-506
    PubMedGoogle Scholar
  • 13 Nieuwenhuizen W, Keyser J. Species specificity in the acceleration of tissue-type plasminogen activator-mediated activation of plasminogen, by fibrinogen cyanogen bromide fragments. Thromb Res 1985; 38: 663-670
    CrossrefPubMedGoogle Scholar
  • 14 Lijnen HR, De Cock F, Matsuo O, Collen D. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis 1992; 6: 33-37
    PubMedGoogle Scholar
  • 15 Lijnen HR, Marafino BJ, Collen D. In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species. Thromb Haemost 1984; 52: 308-310
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Lijnen HR, De Wreede K, Demarsin E, Collen D. Biological and thrombolytic properties of human urokinase-IV. Variability in fibrinolytic response of plasma of several mammalian species. Thromb Haemost 1984; 52: 31-33
    PubMedGoogle Scholar
  • 17 Dempfle CE, Heene DL. Purification of human plasma fibrinogen by chromatography on protamin-agarose. Thromb Res 1987; 46: 19-27
    CrossrefPubMedGoogle Scholar
  • 18 Nieuwenhuizen W. Study on the catabolism and distribution of fibrinogen in rats. BBRC 1980; 97: 49-55
    PubMedGoogle Scholar
  • 19 Moroz LA, Gilmore NJ. A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay forplasmin. Blood 1975; 46: 543-553
    PubMedGoogle Scholar
  • 20 Gough SC, Smyllie J, Sheldon T, Rice PJ, Grant PJ. The anatomical distribution of plasma fibrinolytical activity in man during cardiac catheterisa-tion. Thromb Haemost 1992; 68: 442-447
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Yoshitomi F, Tanaka K, Taniguchi Y. Local fibrinolytic activity of human optic nerve vessels. Ophthalmic Res 1984; 16: 239-245
    CrossrefPubMedGoogle Scholar
  • 22 Ljungner H, Bergqvist D. Comparison of plasminogen activator activity in human arteriesand veins. Thromb Res 1983; 31: 779-786
    CrossrefPubMedGoogle Scholar
  • 23 Lang IM, March JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 1990-2000
    CrossrefPubMedGoogle Scholar
  • 24 Felez J, Chanquia CJ, Levin EG, Miles LA, Plow EF. Binding of tissue plasminogen activator to human monocytes and monocytoid cells. Blood 1991; 78: 2318-2327
    PubMedGoogle Scholar
  • 25 Emeis JJ, Kluft C. PAF-catheter-induced release of tissue-type plasminogen activator from vessel walls. Blood 1985; 66: 86-91
    PubMedGoogle Scholar
  • 26 Van Giezen JJJ, Boon GdIA, Jansen JWCM, Bouma BN. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue-type plasminogen activator (t-PA) activity and inhibitsvenous thrombosis. Thromb Haemost 1993; 69: 381-386
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Bulens F, Nelles L, Van den Panhuyzen N, Collen D. Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells: relation of structure to effect. J Cardiov Pharm 1992; 19: 508-514
    PubMedGoogle Scholar
  • 28 Gelehrter TD, Sznycer-Lasuk R, Zeheb R, Cwickel BJ. Dexamethasone induced inhibition of tissue-type plasminogen activator (t-PA) activity: paradoxical induction of both t-PA antigen and plasminogen activator inhibitor. Mol Endocrinol 1987; 1: 97-101
    CrossrefPubMedGoogle Scholar